New drug combo shows promise for rare lymphoma in phase II trial
NCT ID NCT03697512
First seen Jan 18, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This phase II trial is testing a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma (MZL), a type of blood cancer. The study aims to see how well the treatment controls the disease and how safe it is. About 175 participants with different MZL subtypes will receive the combination therapy and be followed for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
A.O. Spedali Civili di Brescia
Brescia, 25123, Italy
-
A.O.U. Città della Salute e della Scienza di Torino Ospedale Molinette
Torino, TO, 10126, Italy
-
AAST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
Azienda Ospedaliera Arcispedale Santa Maria Nuova IRCCS
Reggio Emilia, 42123, Italy
-
Azienda Ospedaliera Universitaria Ospedali Riuniti - Università Politecnica delle Marche
Ancona, 60100, Italy
-
Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)
Trieste, Italy
-
CHRU de Strasbourg
Strasbourg, 67091, France
-
CHU Dijon Bourgogne - Hôpital François Mitterand
Dijon, 21000, France
-
CHU UCL Namur / site Godinne
Yvoir, B5530, Belgium
-
CHU d'Estaing
Clermont-Ferrand, Cedex 1, 63003, France
-
CHU de Grenoble - Hôpital Albert MICHALLON
La Tronche, 38700, France
-
CHU de Montpellier
Montpellier, Cedex 05, 34295, France
-
CHU de Nancy - Hôpital Brabois
Vandœuvre-lès-Nancy, 54500, France
-
CHU de Rennes Pontchaillou
Rennes, Cedex 9, 35033, France
-
CHU de Tours - Hôpital Bretonneau
Tours, Cedex 01, 37004, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Fondazione IRCCS - Cà Granda - Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Fondazione IRCCS - Policlinico San Matteo
Pavia, 27100, Italy
-
Giovanni Paolo II/I.R.C.C.S. Istituto Tumori
Bari, 70124, Italy
-
Hôpitaux Universitaires de Genève
Geneva, 1211, Switzerland
-
IHBN - CHU Côte de Nacre
Caen, 14033, France
-
IUCT Oncopole Toulouse
Toulouse, 31100, France
-
Inselspital Bern
Bern, 3010, Switzerland
-
Institut Bergonié
Bordeaux, 33076, France
-
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.
Lisbon, 1099-023, Portugal
-
Istituto Oncologico della Svizzera Italiana (IOSI)
Bellinzona, Canton Ticino, 6500, Switzerland
-
Kantonalspital Baden
Baden, 5404, Switzerland
-
Ospedale Oncologico Businco
Cagliari, 09121, Italy
-
Ospedale San Raffaele
Milan, MI, 20132, Italy
-
Ospedale degli Infermi
Ponderano, BI, 13875, Italy
-
Ospedale di Circolo e Fondazione Macchi di Varese
Varese, 21100, Italy
-
Saint Louis Hospital
Paris, 75010, France
-
U.O. Ematologia AUSL Ravenna
Ravenna, 48121, Italy
-
Università degli Studi di Roma La Sapienza
Roma, 00185, Italy
-
Universitätsspital Zürich
Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.